SEC Company Response from Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353) (EOCN) — Mar 11, 2014
Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353)
Date: March 11, 2014 · CIK: 0001595353 · Accession: 0001144204-14-014804
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-193792
Letter
Via EDGAR Division of Corporation Finance Filed February 28, 2014 As amended by Amendment No. 2 to Registration Statement on Form F-1 Filed March 11, 2014 File No. 333-193792
Dear Mr. Riedler:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned hereby joins in the request of Galmed Pharmaceuticals Ltd. that the effective date of the above-referenced Registration Statement be accelerated so that the Registration Statement may become effective on Wednesday, March 12, 2014, at 4:00 p.m. (Washington D.C. time), or as soon thereafter as may be practicable.
In accordance with Rule 461 of the Act, we, acting as representative of underwriters, wish to advise you that, between February 6, 2014 and March 11, 2014, we distributed a total of approximately 1,800 copies of the Preliminary Prospectuses dated February 6, 2014, February 28, 2014 and March 11, 2014, of which approximately 200 copies were distributed to other underwriters. The majority of these copies were distributed to investors, including individuals and institutions. Copies of the Preliminary Prospectus were available to anyone requesting the same at the offices of the underwriters.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Sincerely,
Maxim Group llc
Show Raw Text
CORRESP
1
filename1.htm
Maxim Group LLC
405 Lexington Ave
New York, NY 10174
March 11, 2014
Via
EDGAR
Division of Corporation
Finance
U.S. Securities and Exchange
Commission
Washington, D.C. 20549-0404
Attn: Jeffrey P. Riedler,
Assistant Director
Re:
Galmed Pharmaceuticals Ltd.
Registration Statement on Form F-1
Filed February 6, 2014
As amended by Amendment No. 1 to Registration Statement on Form F-1
Filed February 28, 2014
As amended by Amendment No. 2 to Registration Statement on Form F-1
Filed March 11, 2014
File No. 333-193792
Dear Mr. Riedler:
Pursuant to Rule 461 of the General Rules
and Regulations under the Securities Act of 1933, as amended, the undersigned hereby joins in the request of Galmed Pharmaceuticals
Ltd. that the effective date of the above-referenced Registration Statement be accelerated so that the Registration Statement may
become effective on Wednesday, March 12, 2014, at 4:00 p.m. (Washington D.C. time), or as soon thereafter as may be practicable.
In accordance with Rule 461 of the Act,
we, acting as representative of underwriters, wish to advise you that, between February 6, 2014 and March 11, 2014, we distributed
a total of approximately 1,800 copies of the Preliminary Prospectuses dated February 6, 2014, February 28, 2014 and March 11, 2014,
of which approximately 200 copies were distributed to other underwriters. The majority of these copies were distributed to investors,
including individuals and institutions. Copies of the Preliminary Prospectus were available to anyone requesting the same at the
offices of the underwriters.
The undersigned confirms that it has complied
with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied
with or will comply with, Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced
issue.
Sincerely,
Maxim Group llc
As Representative of Underwriters,
/s/ Clifford A. Teller
By: Clifford A. Teller
Title: Executive Managing Director, Investment Banking